A research project funded by The Horse Trust has made important discoveries about how two peptides regulate the inflammatory response in horses. This knowledge could help with the development of improved anti-inflammatory drugs, which are used to treat a wide range of conditions in horses.
The research project was led by Professor Fiona Cunningham at the Royal Veterinary College in Hertfordshire and Dr Karen Rickards at the Donkey Sanctuary in Sidmouth, assisted by Dr Andrew Brooks at the RVC, and by Dr Kirstie Pickles, now at the Royal (Dick) School of Veterinary Studies in Edinburgh.
Inflammation is associated with a wide range of equine diseases, including recurrent airway obstruction, laminitis and sweet itch. Anti-inflammatory drugs, such as glucocorticosteroids, mainly work by blocking the formation and/or actions of compounds produced in the horse's body that cause inflammatory responses. However, these drugs are not always effective and can have unwanted side effects.
This research, funded by The Horse Trust, aimed to find out more about two naturally-occurring peptides - chains of amino acids that are shorter than proteins - known as annexin-1 and CXCL8. Both have been shown to affect the inflammatory response but little research has been done on their effects in horses. In the long term, knowing more about these compounds could help in the development of new anti-inflammatory drugs with fewer side effects.
During inflammation, neutrophils (a type of white blood cell) stick to the cells lining blood vessels and migrate into inflamed tissue, where they ingest and break down harmful agents. Using techniques that mimic these events, CXCL8 was found to cause adherence and migration of horse neutrophils. However, when it was used in combination with another pro-inflammatory substance, neutrophil migration and adherence were markedly decreased. This suggests that attempts to reduce inflammation by blocking the actions of CXCL8 might not be as beneficial as had been thought.
At the start of the project, the researchers had no information about horse annexin-1, other than its gene sequence, so their first step was to develop a method to detect the peptide in white blood cells. They established that it was present and, as horse annexin-1 has not yet been synthesised, they used a synthetic peptide derived from annexin-1, Ac2-26, to look at the effects on horse neutrophils.
They found that Ac2-26 decreased neutrophil adherence and migration in response to other pro-inflammatory compounds, although at high concentrations the peptide itself caused some cell activation, thereby increasing inflammation. They also found that dexamethasone (a glucocorticosteroid) increased the levels of annexin-1 in cells, indicating that, as in humans, this class of drugs is likely to act in part through the formation of annexin-1.
These findings suggest that the use of compounds which mimic the actions of annexin-1 may have limitations as anti-inflammatory drugs. As glucocorticosteroids partly work by forming annexin-1, further research is needed in order to find out how annexin-1 will act in the horse's body and establish how its formation contributes to the beneficial effects of these drugs.
Professor Cunningham said: "This Horse Trust-funded research has resulted in some very interesting findings about how inflammatory cells are regulated in horses. The receptors that annexin-1 and CXCL8 act upon could be targets for new equine inflammatory drugs, but more research is needed first to fully understand their actions and how they produce these effects."
The team's research has been accepted for publication by the journal Veterinary Immunology & Immunopathology.
Animal Health and Veterinary Laboratories Agency (AHVLA) has announced the formation of a new independent advisory group to recommend a future delivery model for veterinary surveillance in England and Wales.
The Advisory Group will be chaired by Dirk Pfeiffer, Professor of Veterinary Epidemiology at the Royal Veterinary College. According to the AHVLA, it will include representatives from government, the veterinary profession and the livestock farming and private laboratory industries and is being created so all those with an interest in veterinary surveillance can shape a future model and ensure that all issues are thoroughly considered.
Veterinary surveillance seeks to identify new or re-emerging threats to our livestock population and to public health. It involves a partnership approach between livestock keepers, private veterinary surgeons, the Scottish Agricultural College, industry bodies and AHVLA in order to effectively gather and assess intelligence.
AHVLA is seeking to identify ways to undertake veterinary surveillance both more effectively and at an affordable cost to the taxpayer. Work in this area has been on-going since 2010, and the merger of the former Animal Health and Veterinary Laboratories Agency (VLA) has created opportunities to review how veterinary surveillance can best be delivered.
The new model will aim to address capacity imbalances in the current service where provision sometimes outstrips demand. The independent advisory group are also expected to recommend how better and closer working methods across the partners can make the surveillance stronger as well as more cost effective.
Surveillance has historically been based on in-depth investigation of disease incidents with an emphasis on post mortem examinations carried out at AHVLA's regional laboratories. This system is a key element in the government's risk-based approach to the management of animal disease related threats.
AHVLA says that the current model, although successful in identifying diseases in the past, can be improved upon. A recent internal AHVLA report identified viable options for achieving better surveillance at the same or lower cost by, for example, exploring moving towards risk and intelligence based surveillance and improving the value added by working more closely in partnership with vets and their farmer clients and other sources of intelligence data.
In mid-January 2012, AHVLA will also be publishing, and publicising, an online survey aimed at individual veterinary practioners and livestock keepers. The survey will seek individual opinions on the inputs, mechanisms, outputs and value of surveillance in England and Wales Work is expected to run until spring 2012, following which recommendations on a way forward will be made.
Carl Padgett, President of the BVA, said: “Veterinary surveillance is an essential component in our animal health, public health, food security, and international trade work.
“The emergence of Schmallenberg virus in ruminants in northern Europe demonstrates the current value and ongoing need for a robust surveillance system to work both nationally and internationally.
“The BVA welcomes the establishment of the advisory group and particularly the wide range of veterinary expertise and experience that is represented on the group. It is important that views from both veterinary practitioners and veterinary scientists are fed into this review.
“While we understand that AHVLA and Defra must ensure value for money from the surveillance network, any future model must be shaped by good surveillance strategies, not the need to cut costs.
“We urge all practitioners in England and Wales to contribute to the discussions by completing the online survey.
“We look forward to engaging with the advisory group as it carries out the review and beyond.”
The RCVS Disciplinary Committee has accepted an application for restoration to the RCVS Register by James Main, who was struck off in 2011, following his administration of a prohibited substance to a racehorse and his subsequent attempts to conceal his actions.
At a Disciplinary Committee hearing held on 22 February 2011, Mr Main, a partner in the O'Gorman, Slater, Main & Partners veterinary practice in Newbury was found guilty of serious professional misconduct and his name was removed from the Register. The then-Committee established that, contrary to the British Horseracing Authority's (BHA) rules of racing, Mr Main had injected tranexamic acid into the racehorse 'Moonlit Path' on 19 February 2009, knowing that the horse was to race later that day. He was also found guilty of dishonestly concealing this injection in his practice records as a "pre-race check".
At yesterday's hearing, the Committee noted that the decision to remove Mr Main from the Register had sent a clear message to the profession of the importance of strict compliance with the BHA's Rules of Racing; it was the inevitable consequence of his breaches of those rules and his dishonesty in concealing the administration of the injection. In oral evidence, Mr Main said he accepted the findings and decision of the previous Committee, and he apologised.
The Committee also noted a number of changes since implemented at Mr Main's practice, including a pharmacy review to improve traceability of drugs; withdrawal of the use of tranexamic acid in the management of Exercise Induced Pulmonary Haemorrhage; and a cautious approach to drug withdrawal times. Mr Main's practice had also reviewed its processes to ensure its veterinary surgeons complied with all relevant rules, regulations and guidance, and that any requests by clients to breach these rules would be refused.
The Committee accepted evidence that Mr Main had worked in a management capacity in his practice since 26 March 2011, performing no clinical role, and had undertaken appropriate continuing professional development since being removed from the Register. It also noted the large volume of testimonials and public support presented at the hearing from both veterinary surgeons and clients in the horse world.
Furthermore, it noted that removal had been financially and emotionally detrimental to Mr Main, his family and practice and, if his name were not restored to the Register, there would be a continuing detrimental effect on his family finances and the practice.
Committee Chairman Professor Peter Lees said: "The Committee accepts that Mr Main has found the removal of his name from the Register a humbling and salutary experience and accepts his apologies. It is satisfied that he is very unlikely to breach the rules of racing in the future and does not consider that there is a risk to the future welfare of animals by restoring his name to the Register.
"The Committee does not consider that any further period of erasure would be of benefit either to the public or the veterinary profession."
The Committee directed that Mr Main's name be restored to the Register.
The move comes as the whole agriculture industry, co-ordinated by agricultural and food industry alliance RUMA (which promotes responsible use of medicines in farming), looks to build on the recent 10% reduction in use of antibiotics to treat farm animals.
The BCVA’s Dr Elizabeth Berry, who prepared the recommendations, said that whilst the responsible use of antibiotics has been promoted for many years across farming sectors, there is still the potential to reduce use in some areas and to move away from products which are important for human health.
She said: "This is an official position from BCVA to our members but we would like to see all in the cattle sectors embrace these recommendations in the understanding that we need to play our part in increasing responsible use of antibiotics.
"Work still needs to be done to establish the levels currently being used in cattle so that appropriate targets can be set but there are measures that can immediately be adopted.
"So we are recommending reducing both the overall amount of antibiotics used in cattle practice and minimising the use of the high priority CIAs – namely third and fourth generation cephalosporins, fluoroquinolones and colistin. These drugs should only be used where they have been demonstrated by sensitivity testing to be the only suitable choice to avoid unnecessary suffering."
The BCVA, which has over 1,100 practising members covering around 85% of vets working with cattle, is also recommending that use of antibiotics as a preventative treatment is avoided wherever possible as long as animal welfare is not compromised.
Dr Berry added: "Where preventative treatment – or prophylaxis – is used it should be regarded as an interim measure whilst alternative management or vaccination strategies are implemented.
"For example, all cows which comply with recommendations for using an internal teat sealant should be considered for non-antibiotic treatments at drying off."
The BCVA continues to advise that every farm should have a herd health plan which embraces all of the disease control strategies appropriate for disease reduction on that farm. In addition, farm management best practice should be followed, such as the guidelines issued by Red Tractor farm assurance.
Dr Berry says BCVA further recommends that all herds should establish their BVD status and eradicate the disease where it is found. "BVD can have a detrimental effect on incidence of many diseases and its eradication will have a significant impact on the need for antimicrobial use.
"We also continue to recommend the use of diagnostics to identify disease so that appropriate treatments can be selected and vaccination programmes instituted to prevent or reduce the severity of disease."
BCVA’s confirmation of its official position has been welcomed by RUMA. Secretary General John FitzGerald says that while RUMA’s promotion of responsible use over the past 20 years means the UK remains among the lower users of antibiotics in farming in Europe1, more needs to be done.
"The BCVA’s position is clear and leaves no doubt that action needs to be taken,” says Mr FitzGerald. “It is underpinned by science, recognising that banning preventative use outright or access to critically important antibiotics is not an answer. Both are important tools in fighting disease and preventing suffering so we still need them – but we need to use them more strategically and only when no other options exist."
The complete list of guidelines can be downloaded from the BCVA website www.bcva.eu.
The BSAVA says the guidelines aim to bridge differing perceptions of welfare around the world and help veterinary surgeons tackle the ethical questions and moral issues which impact welfare. They also offer guidance to ensure that, in addition to providing physical health advice and therapy to their patients, vets can advocate for their psychological, social and environmental wellbeing.
Shane Ryan, President of the WSAVA and former Chair of the WSAVA Animal Wellness and Welfare Committee, said: "As veterinarians, our responsibility extends far beyond the physical health of our patients. Animal welfare as a science is a new and rapidly developing discipline and veterinarians need current, evidence-based information to enable them to maintain the highest welfare standards and to provide knowledgeable, accurate advice for pet owners and communities.
"Our new Guidelines provide recommendations, checklists and other tools to promote optimal levels of welfare throughout the veterinary visit. They also offer guidance on increasing welfare beyond the doors of the clinic through outreach activities.
"As levels of pet ownership increase in many regions of the world, including Asia, it is essential that veterinarians champion animal welfare and the WSAVA hopes that these new Guidelines will encourage our members to adopt best practice and set the highest standards.”
Merial has announced the launch of V LINE, a new range of parasiticides sold exclusively through veterinary practices.
The first two products, called Broadline for cats and NexGard for dogs, will be unveiled at the BSAVA Congress at the start of next month.
Broadline is a broad-acting POM spot-on for cats containing eprinomectin, praziquantel, s-methoprene and fipronil, indicated for use against tapeworms, ticks, roundworms and fleas.
NexGard is a POM flea and tick control product for dogs given monthly as a palatable soft chew. It contains a novel active ingredient called afoxolaner which, according to Merial, has a new and distinct mode of action that provides a fast speed of flea kill.
Roddy Webster, Head of Pets at Merial said: "We are pleased to announce the launch of Broadline and NexGard. Merial is a market leader with a strong heritage in anti-parasitics and we have leveraged that expertise as well as our understanding of what pet owners want, to deliver these truly consumer-focused solutions. Such prescription-only innovations also demonstrate our ongoing commitment to the veterinary profession."
According to the charity, one in ten homeless people have a pet, which is around 32,000 people in the UK. However, the majority of hostels do not accept animals, so they are unable to access accommodation.
The new StreetVet Accredited Hostel Scheme will make sure that hostels are well-equipped to support pet-owning residents. This includes having a variety of pet-friendly health, hygiene and safety policies; access to vet care including telemedicine, free provision of pet essentials, transport to vet practices when needed, emergency kennelling should the pet owner be taken ill and trained hostel team members able to offer support.
The scheme - which will roll out nationwide – has launched today with its first accredited site, The Elms in Hemel Hempstead.
The charity was able to launch the programme after winning £41,000 in funding from Purina’s BetterwithPets Prize which rewards social entrepreneurs and innovators seeking to harness the pet-human bond to tackle societal issues.
StreetVet co-founder Jade Statt MRCVS said: “Under current regulations, if people turn down housing due to 'no pets' clauses, they are told they are making themselves 'intentionally homeless' and are refused further housing assistance. Any pet lover will understand that choosing between a roof over your head and the company of your beloved pet is no choice at all.
"Our hope is that in setting up the StreetVet Accredited Hostel Scheme, fewer people will have to make this impossible choice. Access to pet-friendly hostels is their first step towards independent housing. With homelessness on the rise due to the economic impact of COVID-19, it was important to us to launch this scheme before Christmas, as winter sets in."
Bernard Meunier, Purina EMENA chief executive said: “This great achievement demonstrates how a programme built on deep love for pets and their owners, and belief in the power of the pet-human bond, can deliver positive change for both individuals and communities. And this is what we want to achieve with ourBetterwithPets Prize.”
For more information, visit https://www.streetvet.org.uk
The researchers say that previous research suggests that approximately 10% of diabetic cats are euthanised at the time of diagnosis, making it a significant cat welfare issue.
However, this figure was largely based on questionnaire-based research from several global locations.
This new study followed the survival of 1,053 cats with confirmed diabetes mellitus under UK primary-care practices in 2019, providing the most up-to-date baseline data on early death among diabetic cats in the UK, as well as examining risk factors for the development of diabetes among UK pet cats.
The study found:
Based on these findings, the researchers encourage veterinarians to more actively discuss diabetes mellitus risk with cat owners, particularly those with Burmilla and Burmese breeds, in the hope that raising awareness of the disease might improve outcomes through earlier diagnosis, and by taking actions that might prevent diabetes mellitus development in the first instance, such as preventing cats becoming obese.
Dr Oliver Waite, Senior Lecturer in Small Animal Medicine at Murdoch University, and primary author of the paper, said: “We hope that this new, large scale epidemiological study, investigating the second most common endocrine disease in cats, will help to highlight current as well as future areas to improve cat welfare.
"This is an exciting time for the management of diabetic cats but more work is still needed!”
Dr Dan O’Neill, Associate Professor in Companion Animal Epidemiology at the RVC, and co-author of the paper, said: “This new VetCompass study shows the value of everyone working in primary care practice sharing their anonymised clinical data to get a better understanding of real-world animal health.
"Awareness of the scale of the diabetes mellitus issue revealed here can empower veterinary professionals to engage in more conversations with owners about diabetes mellitus prevention in predisposed cats.”
Reference
Novartis Animal Health has announced that it has assumed marketing responsibilities for the joint health supplement Cosequin in the United Kingdom and Ireland.
Cosequin, which contains glucosamine and chondroitin sulfate, is available in a range of presentations for dogs, cats, and horses.
The product, which was previously marketed by MSD, is the leading joint health supplement among veterinary surgeons in the US and Europe.
Novartis says Cosequin is an important addition to its Orthopaedic Health Category, which in 2009 introduced Onsior (robenacoxib), the first tissue-selective pain relief for cats and dogs.
Gaynor Hillier, General Manager UK & Ireland Novartis Animal Health said: "Our strategic intent is to expand our presence in orthopaedic health to address prevention, diagnosis, and treatment in a more comprehensive manner. Cosequin represents an important step toward achieving this objective".
Cosequin is available from Novartis Animal Health in the United Kingdom and Ireland, from licensed veterinary wholesalers. For more information on Cosequin, contact your Novartis Animal Health Territory Manager.
Alex is applying the data science he uses in his day job to help local vets at the Olive Ridley Project care for the ancient reptiles.
Six of the seven species of sea turtles are endangered due to human behaviour, many of them killed by poachers for their shells, eggs and meat.
They're also affected by the increasing volume of plastic waste in the sea.
Alex, who normally spends his time leading a team of business intelligence engineers and analysts who provide insights in finance, HR and clinical event reporting, is setting the charity up with practice management software to help it capture clinical records and track the sea turtles.
Alex said: "We’ll be setting up the software, making sure the vets can operate it and then adding all their existing data to it. We’re giving them a powerful tool to capture clinical records and manage turtles over a long period of time.”
“These valuable creatures are hugely important to marine ecosystems and have travelled our seas for the last 100 million years, so I’m delighted to be able to play a part in their conservation.”
For more information on the Olive Ridley Project, visit https://oliveridleyproject.org.
Those who pay their fees after 30 April 2017 will be charged an extra £35 to renew their registration while those who have not paid by 31 May 2017 will be removed from the Register.
You will also need to confirm your registration details, confirm you've met the RCVS requirement for continuing professional development of 105 hours over a three-year rolling period and disclose any new or previously undisclosed convictions, cautions or adverse findings.
The annual renewal can be completed by logging into the ‘My Account’ area of the RCVS website (www.rcvs.org.uk/login). For those members who do not have a valid email address, or have requested a hard copy of the renewal form, a form has been sent by post.
Any veterinary surgeons who have not received their annual renewal form or security details for the ‘My Account’ area by 7 March should contact the RCVS Registration Department on 020 7202 0707 or registration@rcvs.org.uk as soon as possible.
Those with queries about paying the annual renewal fee should contact the RCVS Finance Team on 020 7202 0723 or finance@rcvs.org.uk
PBD Biotech says the Actiphage test offers the potential to revolutionise control of bovine TB by allowing detection of the disease within hours from a blood or milk sample.
Last November, the Welsh Government announced a new policy that allowed the use of non-validated tests such as Actiphage in herds affected by a TB breakdown. It followed a similar protocol to one authorised by the UK Government last year for cattle herds in England after the test was used as part of a successful private eradication plan on a Devon dairy farm.
Mossman Farming, in Ceredigion, is located in an area of chronic breakdown. It is a spring-calving milking herd with a total stock of 529, to date 312 dairy cows have been slaughtered. Farmer Chris Mossman agreed to trial Actiphage after hearing about the Gatcombe pilot.
Chris said: "TB is a massive problem in Ceredigion, so when I heard about Actiphage’s use at Gatacombe, helping to clear that dairy herd for the first time in six years, I wanted to try and replicate those findings here. Me – and many other farmers – are losing large numbers of animals. I’m trying to do all I can to get rid of this disease from my herd."
In Spring 2019, The Office of the Chief Veterinary Officer for Wales granted permission for Robert Price-Jones MRCVS to use Actiphage to screen high-risk cattle for M. bovis.
Robert, who has been leading the trial, said: "Actiphage is able to identify the presence of relatively low numbers of M. bovis in the blood stream of infected cattle. It is not dependent upon an immune system response to the pathogen - in contrast to current validated tests - and so has greater sensitivity than such as the official Tuberculin SICCT skin test.
"The benefit of using Actiphage is that it offers the potential for eradicating the disease from the farm; as early identification of animals at risk of bovine TB enables heightened disease management and control."
Under the terms of the Welsh Government’s protocol, cattle not condemned for slaughter can be tested with Actiphage. Those that give a positive result are identified with a ‘management’ marker, monitored and milked separately.
To prevent further contamination of the environment and to minimise risk to uninfected cattle, animals found to be ‘shedders’ are removed from the farm.
Although a decision to remove cattle based on a non-validated test will be at the farmers’ own expense, the APHA (Animal and Plant Health Agency) has confirmed that during the trial, where a positive result is confirmed with statutory tests, the animals will be removed with compensation as normal.
So far, 100 animals from Mossman Farming have been tested with Actiphage and Robert Price-Jones is preparing a paper to publish the findings in early 2020.
PBD Biotech is now seeking more farms to trial Actiphage in order to gain the World Organisation for Animal Health (OIE) validation. The company is offering reduced cost testing to support trials where the findings are made available to support validation of the test.
Pfizer Animal Genetics is expanding its presence in the UK with the appointment of a dedicated team.
The company says it will use state-of-the-art genetic technology to improve the health, welfare and productivity of animals, and that the move comes at an exciting time for genetic research, as complete sequencing of the bovine genome has resulted in explosive growth of the possibilities.
As well as being able to provide tests addressing parentage (SireTRACE) and traceability (SureTRAK), Pfizer Animal Genetics can also help farmers identify the genetic potential that each animal has to produce tender, well marbled meat and to perform at optimal feed conversion efficiency (GeneSTAR) - vital management information that can improve profitability and enable effective decision making in long term breeding plans.
The company promises there is more to come, with exponential growth in the identification of genetic markers, which will allow the imminent introduction of new tests set to provide much more detailed predictive information about individual animals - all available virtually from birth onwards.
Richard Chew (above right) is Customer Service Manager and the first port of call for anyone with questions about pricing & submission forms, samples and reports. Richard grew up in rural Lancashire and went on to study at the University of Bristol. Since graduation his career has taken him through a variety of scientific and customer facing roles. He has worked for Pfizer Animal Health for six years in the clinical development of vaccines and pharmaceuticals for livestock and is looking forward to the new challenges of the genetics business. Richard is based in Pfizer's Surrey office and can be reached on 08345 3037398 or PfizerAnimalGenetics-EU@pfizer.com.
Mike Marron and Peter Quigley are Dairy Sales Manager and Beef and Sheep Sales Manager respectively and will be the contact points for breed associations, organisations and individuals who want to discuss how genetic assessment and identification can help assure the quality of a breed or herd. Mike has an honours degree in biological and biochemical science and a decade of experience in the animal health industry, with special interests in fertility and calf management. Peter also comes from the animal health industry and is looking forward to continuing the company's work with the Aberdeen Angus Society as well as developing programmes for other beef breed societies.
Mike or Peter will be in attendance at various agricultural shows across the UK including Agrilive, the South West Dairy Show, Surecalf, Agriscot, Thainstone Christmas Classic, the Welsh Winter Fair, The Great Yorkshire Show and the Northern Ireland Winter Fair, where they will be explaining how genetic testing can make a contribution towards improving the brand value of a breed and shortening the time frame to allow better management decisions to be made.
Dr Gary Evans is Technical Services Manager and will be providing detailed advice on how to improve pedigree herd books, the interpretation of results of genetic testing and detection of certain genetic diseases. Gary is a geneticist with fourteen years experience in the application of genomics to livestock and joins Pfizer Animal Genetics from PIC/Genus.
Virbac is offering a free Rapid Romanowsky stain kit and Coplin jars to practices buying easOtic and Epi-Otic in a new promotion which runs until the end of October.
easOtic is Virbac's treatment for otitis externa. It features a 1ml airless pump for precise measurement and an award-winning bottle design to aid compliance by ensuring easy and accurate application.
Epi-Otic is Virbac's antibacterial and antifungal ear cleaner for use in routine cleaning. It is pH neutral and contains sodium docusate, which dries the ear canal after application.
Practices making a qualifying purchase of both products will receive the Stain Kit, comprising the three staining solutions and three Coplin jars, free of charge.
For further information, contact your Virbac Territory Manager.
MSD Animal Health showed off Expertis LivestockPro, its new digital flock health management tool, to sheep producers at the NSA Sheep Event last week.
Expertis LivestockPro is an online website-based computer application designed to make flock vaccine and animal health product scheduling much simpler. MSD says it will provide a platform for vets to help their customers improve flock performance and productivity.
Project co-ordinator Marcus Sanders from MSD Animal Health, said: "Expertis LivestockPro really will make life easier for UK sheep producers. Shepherds will no longer have to rely on memory or written records in a filing cabinet or on a farm office wallchart to schedule animal health treatments. Embracing the new digital system will certainly save time and money, and ultimately reduce livestock losses from key sheep diseases."
The new application also keeps track of vaccine stock levels on the farm and reminds users to order additional product before it is needed. Users can set up various alerts on any Internet-connected device. LivestockPro also incorporates medicinal product information and advice on correct vaccine administration.
For more information, visit www.livestockpro.co.uk or e-mail MSD Animal Health [livestockpro@merck.com].
The support pack is available now for existing stockists; others can sign up for a pack (whilst stocks last) at the London Vet Show in November, where Lintbells will be at stand U50.
According to the company, an estimated 15% of canine cases presented at first opinion practices are musculoskeletal and cats are also commonly affected.1
The Mobility Matters support materials are designed to help practices communicate the issues to clients, both in the waiting area and consulting room and online. There are also resources to help behind the scenes with setting up the clinics, including the new guide.
Gemma Cunningham, Lintbells Product Marketing Executive said: "We’re keen to bring attention to nurse-led clinics, which are not just great for patients but great for business too. Measurable outcomes include client satisfaction, incremental sales and improved patient comfort or quality of life. We’ve taken into account existing barriers based on what veterinary teams have told us and created the pack to address those needs. Our Mobility Matters referral cards, which help vets signpost clients to the clinics are a brilliant example of how the pack can help teams work more effectively together."
For more information, contact Lintbells on 01462 790886.
The BVA has added its voice to calls for the suspension of imports of cattle and sheep from areas where the bluetongue virus is known to be circulating.
Following yesterday’s announcement by Defra that BTV1 (Bluetongue Serotype 1) had been detected in five cattle imported from a Restricted Zone in the south west of France, BVA President Nicky Paull said: “I am saddened, but not surprised, that the actions of some are putting our livestock here in the UK at risk. As long as some farmers continue to import stock from these areas we will continue to see this problem and we therefore believe that the only answer is to suspend imports. We also see absolutely no reason why compensation should be paid to those who have risked the health and welfare of the national flock and herd.
“My advice to farmers still is to vaccinate against BTV8 if you have not done so already. If you did vaccinate during the summer then plan to boost protection at the end of the winter period so your stock is protected next summer. With no vaccine currently licensed for BTV1 however, do not import livestock from mainland Europe - we should not rely on the hope of a BTV1 vaccine in time to prevent serious problems next summer if we buy this new strain of bluetongue virus into the UK.”
Eurovet has launched Octacillin Pig, a water-soluble amoxicillin powder for treating pneumonia caused by Actinobacillus pleuropneumoniae and meningitis caused by Streptococcus suis.
Octacillin is widely used in poultry and has recently been approved for use in pigs. Eurovet says Octacillin Pig is ideal for delivery via automatic water systems, as it dissolves completely in hard or soft water and remains stable in solution for 12 hours. It has a withhold period of 2 days.
Pneumonia caused by Actinobacillus pleuropneumoniae tends to affect pigs at 8-16 weeks of age and has a very short incubation period of just 12 hours.
Octacillin Pig will be available from early March.
For further information call 01223 257933.
Bayer Animal Health, maker of Advocate, has announced that it will be running its 'Be Lungworm Aware' campaign in April.
The company says the campaign aims to help raise awareness of Angiostrongylus vasorum amongst dog owners and support the veterinary practice as a source of further information. The initiative will be backed by a national TV and print advertising campaign. Media vet Joe Inglis will also be supporting the initiative and will be talking about Angiostrongylus vasorum during a series of radio and web broadcasts.
Bayer has produced new support materials, including an updated lungworm PR pack. The materials are designed to allow veterinary practices to educate owners on the disease, whilst helping to raise the profile of the practice in the local community.
Meanwhile, the research carried out by the company has revealed some interesting insights into dog owners' understanding of lungworm.
Despite awareness being fairly high with nearly half of owners claiming to know about the condition, 84% of this group did not know any of the clinical signs associated with the infection, while only 60% were aware that the disease could be fatal if left untreated. Understanding of how dogs become infected was also relatively low with only 24% of owners recognising the role of slugs and snails as the intermediate host for the parasite. As well as playing a vital role in alerting owners to the emergence of the disease, the veterinary practice was cited as the primary source of information that owners would refer to if they needed advice on treating this parasite.
Eric Morgan from the University of Bristol said: "Angiostrongylus vasorum appears to be continuing its spread to new locations in the UK. It is therefore important that dog owners are educated on the infection and the signs to look out for, to enable them to seek treatment before it is too late."
For further details, or to order the new practice materials, please contact your Bayer representative or ring 0845 2574798 quoting 'Be Lungworm Aware'.
ECC vet Shailen Jasani has launched a crowdfunding campaign to raise funds for further development of his pet bereavement website, www.theralphsite.com
The Ralph Site is a non-profit pet bereavement support online resource and Facebook community which Shailen set up in 2011 after the loss of his cat Ralph.
Shailen says that over the past three years, the site has proved to be a much needed resource, with many pet carers benefiting from what it offers and a growing number of practices referring their bereaved clients to the site for information and support, and a sympathetic and empathetic virtual ear. So far, the site has had approximately 60,000 visitors and the Facebook community now stands at an impressive 34,000 Likes.
Shailen manages the site by himself and has has also personally funded all of the expenses to date including design, development, on-going management and promotion costs, to the tune of £30,000.
However, he says he now needs further funds to make the site work properly on smartphones and tablets, improve the memorial section and promote it more widely to pet owners, for which he is turning to crowdfunding and hoping that members of the profession will support what he is doing, both with contributions and by helping spread the word amongst family, colleagues and clients.
Shailen said: "The issue of pet bereavement and the impact of pet loss on their carers is a serious one which is slowly but surely gaining increasing recognition. A resource such as the Ralph Site is invaluable for practices to be able to link and refer clients to. I very much hope colleagues will get behind my campaign."
To find out more about the campaign, visit: http://igg.me/at/theralphsite/x
CVS has announced a two year programme of investment of more than £3 million in two high-field (1.5 Tesla) MRI scanners and seven CT scanners as part of a programme to provide advanced imaging resourcing across the group.
The first of the MRI scanners will be installed at ChesterGates, CVS' multi-disciplinary veterinary referral hospital, in Spring 2015. CVS says it believes it will be the most advanced MRI system for pets in the North West of England.
The seven 16-slice CT scanners will be installed at CVS hub practices, including ChesterGates, PetMedics in Manchester, Beechwood Veterinary Hospital in Doncaster and St David's in Devon.
CVS Referral Director John Innes said: "We are committed to utilising the latest technology across the group and this investment in our scanning capability is a good example. The new MRI scanner at ChesterGates will enhance the high quality specialist referral services we offer, particularly in neurology because MRI is used mainly to image the brain and spinal cord.
"The seven new CT scanners will enable our teams to scan a chest or abdomen rapidly and with outstanding image quality. Image data can be processed and viewed in other planes or 3-D rendered to assist with decision making and surgical planning. The installation of the new CT scanners will be rolled out over the next two years, enabling us to offer cost-effective advanced imaging to many more of our clients across the country."
The event, which is being organised by Colin Whiting MRCVS and his wife Lizzy (also MRCVS), is taking place at Killaworgey Farm, Black Cross, Newquay, TR8 4LU
Performing on the outdoor stage at the event are the Ceilidh Band and Spit Roast, a covers band.
Catering includes a licensed bar, wood-fired pizzas, log-roasted chicken, pulled pork burritos, pasties and cream teas.
There'll be a quiz night, fancy dress and an outdoor showing of the film Trainspotting.
And if all that weren't enough, you'll be just a stone's throw from Newquay and its nearby beaches, and about 30 mins drive from the Eden Project.
Colin said: "The whole vet world family is welcome.
"We've got people coming from Liverpool vet school straight from rotations, practices bringing their EMS student along: bands, bar, party field, outdoor roasts and burritos, indoor pasties and wood-fired pizzas, and - to cap it all - a 6-shower, 8-loo toilet block newly completed for the camping field, with a 2-metre urinal in the gents as well, but that's not so much of a selling point...
"Visitors are very welcome to come earlier or camp longer too; there's a warm welcome for all at Killaworgey."
Fore more information, visit: https://www.killaworgeyfarm.co.uk/
If they become law, the changes proposed by the working party will have a profound effect on all practising veterinary surgeons and nurses, so it could not be more important that you express your opinion, whether that is in support of the changes or against them.
The proposals fall under five main headings below, each of which is linked to a discussion thread on the subject. Of particular note is the 'fitness to practise' section which includes proposals for radical changes to the disciplinary process:
Do come and join in the discussions. Which of these things do you think will improve the veterinary care of animals? Could any of them have consequences that haven't been thought of? Do you think some of them show the College overreaching itself? Or do they not go far enough?
Come and tell us what you think. Hopefully the discussions will help you form your response to the RCVS survey.
The RCVS survey closes at 5pm on 23rd April 2021.
The RCVS Charitable Trust has teamed up with the Foundation for Social Improvement (FSI) for the launch of the Great Big Small Charity Car Draw 2011.
The draw enables small charities, such as the RCVS Charitable Trust, to sell tickets to supporters which offer a chance of winning a brand new Fiat 500 1.2 Pop. Each ticket costs only £2, and the Trust will receive £1.90 for every ticket it sells.
Tickets can be bought securely online at http://trust.rcvs.org.uk/support-us/get-involved/win-a-fiat-500/ or directly from the Trust office on 020 7202 0721 or by emailing fundraising@rcvstrust.org.uk. Books of tickets are also available to sell to colleagues, friends and family. The deadline for buying tickets is September 16th 2011 with the draw taking place on 25th October 2011.
Here are a few examples of what reviewers have been saying about the Fiat 500:
"The Fiat 500 is both stylish and fun. The modest running costs complement the engaging handling. So, this nimble little city car can be enthusiastically thrown into corners and it should emerge grinning like a Cheshire Cat." Motoring.co.uk
"I love my Fiat 500 1.2 Pop from the moment I drove off in it. Great fun to drive on the motorway and in town for parking into slots others cannot!" What Car?
"It's absolutely fantastic. It drives like a dream. Everybody admires it." Fiat Forum
For further information on the car draw, please contact Fiona O'Regan on 020 7202 0743 or Rebecca Fellows on 020 7202 0721. Alternatively email fundraising@rcvstrust.org.uk.
Virbac has launched Inflacam, a meloxicam-based NSAID for the alleviation of pain in both acute and chronic musculo-skeletal disorders in dogs and horses.
Inflacam is presented both as an oral suspension and as a chewable tablet for dogs. The suspension is available in 200ml, 100ml, 42ml and 15ml sizes with a measuring syringe provided. The tablets come in two sizes - 1 mg and 2.5 mg - and are available in packs of 100. It is available for horses as an oral suspension.
Virbac Product Manager Chris Geddes MRCVS, said: "Virbac is well known for launching innovative products in areas such as dermatology and reproduction but we also aim to support practices by offering tried and trusted practice 'standards' for everyday use. Inflacam fits this brief well - meloxicam is the most commonly-used NSAID in dogs and we are delighted to add it to our range."
For more information contact your territory manager or call Virbac on 01359 243 243.